ImmunoTEP for Patients With Medullary Thyroid Carcinoma.

- Histological diagnosis of CMT

- Calcitonin> 150 pg / ml

- Complete treatment of the primary tumor

- at least one detectable lesion more than 10 mm on conventional imaging: bone lesions can be taken into account if they extend outside of the bone and the party extra bone is measurable.

- Age ≥ 18 years

- Negative pregnancy test for women of childbearing age in the previous 2 days immuno-PET. Women of childbearing potential should use effective contraception take continuously for 3 months.

- KPS ≥ 70 or ECOG 0-1 and life expectancy of at least 6 months

- Absence of serious illness or co-morbidity assessed risk

- Creatinine ≤ 2.5 normal

- Absence of cancer treatment within 6 weeks prior to the immuno-PET

- No history of cancer within 5 years, except skin cancer other than melanoma or carcinoma in situ of the cervix

- Lack of anti-antibodies in patients who have previously received antibodies and hypersensitivity to antibody or protein

- Informed consent signed

- Social Insurance

- Pregnancy or breastfeeding

- Serious illness or co-morbidity assessed risk

- History of cancer within 5 years, except skin cancer other than melanoma or carcinoma in situ of the cervix

- Presence of anti-antibodies in patients who have previously received antibodies

- Known hypersensitivity to antibody or protein

- Need to establish a cancer treatment within 3 months of immuno-PET (before stock evaluation 3 months)

- Inability intellectual sign consent

- Patient protected by law